$2.24
5.88% yesterday
Nasdaq, Jun 11, 10:13 pm CET
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Iovance Biotherapeutics Inc Stock price

$2.24
+0.31 16.06% 1M
-6.34 73.89% 6M
-5.16 69.73% YTD
-6.38 74.01% 1Y
-27.38 92.44% 5Y
-8.23 78.61% 10Y
-2.97 56.99% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.14 5.88%
ISIN
US4622601007
Symbol
IOVA
Sector
Industry

Key metrics

Market capitalization $748.01m
Enterprise Value $389.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.83
P/S ratio (TTM) P/S ratio 3.52
P/B ratio (TTM) P/B ratio 0.97
Revenue growth (TTM) Revenue growth 11,035.08%
Revenue (TTM) Revenue $212.68m
EBIT (operating result TTM) EBIT $-398.78m
Free Cash Flow (TTM) Free Cash Flow $-347.50m
Cash position $359.71m
EPS (TTM) EPS $-1.16
P/E forward negative
P/S forward 2.61
EV/Sales forward 1.36
Short interest 28.32%
Show more

Is Iovance Biotherapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.

Iovance Biotherapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Iovance Biotherapeutics Inc forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a Iovance Biotherapeutics Inc forecast:

Buy
67%
Hold
33%

Financial data from Iovance Biotherapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
213 213
11,035% 11,035%
100%
- Direct Costs 166 166
824% 824%
78%
46 46
387% 387%
22%
- Selling and Administrative Expenses 163 163
48% 48%
77%
- Research and Development Expense 274 274
20% 20%
129%
-365 -365
17% 17%
-172%
- Depreciation and Amortization 34 34
28% 28%
16%
EBIT (Operating Income) EBIT -399 -399
15% 15%
-188%
Net Profit -375 -375
17% 17%
-176%

In millions USD.

Don't miss a Thing! We will send you all news about Iovance Biotherapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Iovance Biotherapeutics Inc Stock News

Neutral
GlobeNewsWire
about 16 hours ago
SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically. On May 16, 2025, UBS analysts reportedly slashed their rating on Iovance shares from Buy to Neutral and issued a stark price target cut—from $17 to jus...
Neutral
PRNewsWire
one day ago
BENSALEM, Pa. , June 10, 2025 /PRNewswire/ -- The Law Offices of Howard G.
Neutral
PRNewsWire
2 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1...
More Iovance Biotherapeutics Inc News

Company Profile

Iovance Biotherapeutics, Inc. operates as a biotechnology company. The firm engages in the development and commercialization of novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes, or TIL, which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Head office United States
CEO Frederick Vogt
Employees 838
Founded 2007
Website www.iovance.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today